Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study

BackgroundDotinurad is a novel selective urate transporter 1 (URAT1) inhibitor recently introduced in Japan. This study aims to evaluate the efficacy and safety of dotinurad in hyperuricemic patients with type 2 diabetic kidney disease by comparing serum levels of urate and plasma and urinary levels...

Повний опис

Бібліографічні деталі

Автори:	Takeshi Osonoi, Shinichiro Shirabe, Miyoko Saito, Mitsuru Hosoya, Norie Watahiki, Satako Douguchi, Kensuke Ofuchi, Makoto Katoh
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2025-10-01
Серія:	Frontiers in Endocrinology
Предмети:	febuxostat dotinurad type 2 diabetic kidney disease urate excretion transporter serum urate urate transporter 1 (URAT1)
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1655502/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!